Boston Scientific Cardiology

Primary endpoint met.

Primary endpoint met. The PRAETORIAN DFT trial met its primary endpoint by demonstrating non-inferiority (p < 0.001) of omitting VF conversion testing in patients undergoing de novo S-ICD implant when guided by the PRAETORIAN score. 965 patients were randomized 1:1 into a DFT arm and no-DFT arm. 95% of patients in the no-DFT arm had PRAETORIAN scores less than 90. EMBLEM™ MRI S-ICD System Indications, Safety, and Warnings: https://qrco.de/EMBLEMSICD